Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
HEIDELBERG, Germany, March 23, 2016 -- Affimed N.V. (Nasdaq:AFMD) today announced that on March 30, 2016, the Company will release its financial results for the quarter and year ended December 31, 2015. The Company's management team will host a conference call to discuss the Company's financial results and recent corporate developments on Wednesday, March 30, 2016 at 8:30 a.m. EST. The call can be accessed by dialing one of the numbers listed below five minutes prior to the start of the call and providing the confirmation code 5864817.
| Local - Amsterdam, the Netherlands: | +31 (0) 20 716 8295 |
| Local - Copenhagen, Denmark: | +4532 71 1660 |
| Local – Frankfurt, Germany: | +49 (0) 69 2222 10628 |
| Local - Geneva, Switzerland: | +41 (0) 22 592 79 53 |
| Local - London, U.K.: | +44 (0) 20 3427 1906 |
| Local - New York City, U.S.A.: | +1 212 444 0412 |
| Local - Paris, France: | +33 (0) 1 76 77 22 29 |
An audio webcast of the conference call can be accessed in the "Events" section on the "Media" page of the Affimed website at http://www.affimed.com/events.php. A replay of the webcast will be available on Affimed's website shortly after the conclusion of the call and will be archived on the Affimed website for 30 days following the call.
About Affimed N.V.
Affimed (Nasdaq:AFMD) is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. Affimed's product candidates are being developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that seeks to harness the body's own immune defenses to fight tumor cells. The most potent cells of the human defense arsenal are types of white blood cells called natural killer cells, or NK-cells, and T-cells. Affimed's proprietary, next-generation bispecific antibodies, called TandAbs for their tandem antibody structure, are designed to direct and establish a bridge between either NK-cells or T-cells and cancer cells, triggering a signal cascade that leads to the destruction of cancer cells. Affimed has focused its research and development efforts on three proprietary TandAb programs for which it retains global commercial rights. For more information, please visit www.affimed.com.
IR Contact:
Caroline Stewart, Head IR
Phone: +1 347394 6793
E-Mail: [email protected] or [email protected]
Media Contact:
Anca Alexandru, Head of Communications
Phone: +49 6221 64793341
E-Mail: [email protected]
